Sino Biopharmaceutical Limited
SBMFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,866 | $26,199 | $26,026 | $26,861 |
| % Growth | 10.2% | 0.7% | -3.1% | – |
| Cost of Goods Sold | $5,336 | $4,990 | $5,796 | $5,332 |
| Gross Profit | $23,530 | $21,210 | $21,539 | $21,529 |
| % Margin | 81.5% | 81% | 82.8% | 80.1% |
| R&D Expenses | $5,235 | $4,473 | $4,333 | $3,747 |
| G&A Expenses | $2,082 | $1,873 | $2,205 | $2,185 |
| SG&A Expenses | $12,159 | $11,067 | $12,564 | $12,704 |
| Sales & Mktg Exp. | $10,078 | $9,193 | $9,809 | $10,518 |
| Other Operating Expenses | $0 | $0 | -$944 | $735 |
| Operating Expenses | $17,394 | $15,540 | $15,953 | $17,186 |
| Operating Income | $6,136 | $5,786 | $5,586 | $5,079 |
| % Margin | 21.3% | 22.1% | 21.5% | 18.9% |
| Other Income/Exp. Net | -$858 | -$376 | -$371 | $13,494 |
| Pre-Tax Income | $5,277 | $5,410 | $5,215 | $18,573 |
| Tax Expense | $493 | $797 | $697 | $1,958 |
| Net Income | $3,500 | $2,332 | $2,544 | $14,608 |
| % Margin | 12.1% | 8.9% | 9.8% | 54.4% |
| EPS | 0.2 | 0.079 | 0.11 | 0.78 |
| % Growth | 153.2% | -28.2% | -85.9% | – |
| EPS Diluted | 0.19 | 0.1 | 0.12 | 0.73 |
| Weighted Avg Shares Out | 17,244 | 23,392 | 18,622 | 18,769 |
| Weighted Avg Shares Out Dil | 18,295 | 18,529 | 19,017 | 19,283 |
| Supplemental Information | – | – | – | – |
| Interest Income | $500 | $187 | $196 | $162 |
| Interest Expense | $295 | $495 | $429 | $309 |
| Depreciation & Amortization | $940 | $1,074 | $1,047 | $993 |
| EBITDA | $6,109 | $6,979 | $6,691 | $19,874 |
| % Margin | 21.2% | 26.6% | 25.7% | 74% |